» Articles » PMID: 32964180

The Impact of Disease Severity and Duration on Cost, Early Retirement and Ability to Work in Rheumatoid Arthritis in Europe: an Economic Modelling Study

Overview
Specialty Rheumatology
Date 2020 Sep 23
PMID 32964180
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: RA is a progressive, chronic autoimmune disease. We summarize the impact of disease activity as measured by the DAS in 28 joints (DAS28-CRP scores) and pain on productivity and ability to work using the Work Productivity and Activity Impairment questionnaire (WPAI) scores, in addition to the impact of disease duration on the ability to work.

Methods: Data were drawn from the Burden of RA across Europe: a Socioeconomic Survey (BRASS), a European cross-sectional study in RA. Analyses explored associations between DAS28-CRP score and disease duration with stopping work because of RA, and regression analyses assessed impacts of pain and DAS28-CRP on early retirement and WPAI.

Results: Four hundred and seventy-six RA specialist clinicians provided information on 4079 adults with RA, of whom 2087 completed the patient survey. Severe disease activity was associated with higher rates of stopping work or early retirement attributable to RA (21%) moderate/mild disease (7%) or remission (8%). Work impairment was higher in severe (67%) or moderate RA (45%) compared with low disease activity [LDA (37%)] or remission (28%). Moreover, patients with severe (60%) or moderate pain (48%) experienced increased work impairment [mild (34%) or no pain (19%)]. Moderate to severe pain is significant in patients with LDA (35%) or remission (22%). A statistically significant association was found between severity, duration and pain work impairment, and between disease duration early retirement.

Conclusion: Results demonstrate the high burden of RA. Furthermore, subjective domains, such as pain, could be as important as objective measures of RA activity in affecting the ability to work.

Citing Articles

Adherence to the antirheumatic drugs: a systematic review and meta-analysis.

Aksoy N, Ozturk N, Agh T, Kardas P Front Med (Lausanne). 2024; 11:1456251.

PMID: 39328321 PMC: 11424425. DOI: 10.3389/fmed.2024.1456251.


Association Between the Quality of Life Domains with Anthropometric and Adiposity Indices in Rheumatoid Arthritis: A Cross-Sectional Study from a Single Centre in Erbil-Iraq.

Jalal A, Mawlood Z, Aref S, Al-Nimer M Mediterr J Rheumatol. 2024; 35(2):247-254.

PMID: 39211015 PMC: 11350410. DOI: 10.31138/mjr.230828.jaa.


Examining pain severity in women with rheumatoid arthritis: the impact of pain self-efficacy and perceived partner's emotional support.

cepukiene V, Puzeriene E Health Psychol Rep. 2024; 12(1):14-25.

PMID: 38425891 PMC: 10900974. DOI: 10.5114/hpr/167803.


The causal effect of two occupational factors on osteoarthritis and rheumatoid arthritis: a Mendelian randomization study.

Huang J Front Public Health. 2024; 11:1281214.

PMID: 38410128 PMC: 10895025. DOI: 10.3389/fpubh.2023.1281214.


Signaling pathways in rheumatoid arthritis: implications for targeted therapy.

Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M Signal Transduct Target Ther. 2023; 8(1):68.

PMID: 36797236 PMC: 9935929. DOI: 10.1038/s41392-023-01331-9.


References
1.
Husberg M, Davidson T, Hallert E . Non-medical costs during the first year after diagnosis in two cohorts of patients with early rheumatoid arthritis, enrolled 10 years apart. Clin Rheumatol. 2016; 36(3):499-506. PMC: 5323479. DOI: 10.1007/s10067-016-3470-z. View

2.
Oude Voshaar M, Das Gupta Z, Bijlsma J, Boonen A, Chau J, Courvoisier D . International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. Arthritis Care Res (Hoboken). 2018; 71(12):1556-1565. PMC: 6900179. DOI: 10.1002/acr.23799. View

3.
Smolen J, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6):960-977. DOI: 10.1136/annrheumdis-2016-210715. View

4.
Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J . Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018; 38(6):935-947. PMC: 5953992. DOI: 10.1007/s00296-018-4005-5. View

5.
Reilly M, Zbrozek A, Dukes E . The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4(5):353-65. DOI: 10.2165/00019053-199304050-00006. View